Abstract
Huntington’s disease (HD) is an autosomal dominant neurodegenerative brain disorder. The mutation was identified in 1993 as an expanded CAG repeat that codes for an abnormally high number of glutamines in the huntingtin protein. At present, there is no known treatment to slow the pace of neurodegeneration, which generally leads to death over a 20-year period after clinical diagnosis. The clinical manifestations of the disease vary widely but they generally include dysfunction in cognition, mood, voluntary motor control, and most patients have the signature finding of chorea.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsFurther Reading
Bates, G, Harper, P, Jones L (2002). Huntington’s Disease. 3rd Edition. Oxford University Press, Oxford.
David, A.S., Fleminger, S., Kopelman, M.D., Lovestone, S., Mellers, J.D.C. (2009). Lishman’s Organic Psychiatry: A textbook of Neuropsychiatry. Wiley-Blackwell
Hersch S, Jones, R, KoroshetzW, Quaid K, (1994) The neurogenetics genie: testing for the Huntingtons disease mutation. Neurology 44: 1369–1373.
Huntington Study Group (1996). Unified Huntington’s disease rating scale:reliability and consistency. Movement Disorders. 11: 136-142
Johnson CD, Davidson BL. (2010) Huntington’s disease: progress toward effective disease-modifying treatments and a cure. Human Molecular Genetics. 19: Rev issue 1. R98-R102.
Kayson, E., Darnell, M., Weber, J., Biglan, K., & Shoulsan, I et al. (2004). Depression and suicidality at baseline in the prospective Huntington’s At Risk Observational Study (PHAROS). Movement Disorders, 19, 1128.
Klöppel, S., Stonnington, C.M. et al., (2010). Irritability in pre-clinical Huntington’s disease. Neuropsychologia 48, 549–557.
Krainc D. (2010) Clearance of mutant proteins as a therapeutic target for neurodegenerative diseases. Arch of Neurol. 67: 388–392.
Kremer, B. (2002). Clinical neurology of Huntington’s disease. In G. Bates, P. Harper, L.Jones (Eds). Huntington’s disease (3rd ed. pp.28–61). OUP.
Lundin A, Dietrichs E, Haghighi S. et. al. (2010) Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease. Clin Neuropharmacol. 33:260–264.
Maestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. (2009) Therapeutic interventions for symptomatic treatment in Huntington disease. Cochrane Database Syst Rev. CD006456.
Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I, Huntington’s Study Group. (2009) Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology 73: 385–92.
Mellers, J.D.C. & Pender, N. (2001).Neuropsychiatry of Huntington‘s disease. Advances in Clinical Neuroscience and Rehabilitation, 1, 5, 15–16.
Paulsen J. (2005) Cognitive changes in Huntington’s disease. Advances in Neurology 96:209–225.
Paulsen, S., Langbehn, D.R., Stout, J.C. et al. (2008). Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery and Psychiatry, 79:874–880.
Rosas HD, Feigin AS, Hersch SM. (2004) Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington’s disease. NeruoRx. 1:263–273.
Snowden, J., Crauford, D., Griffiths, H.L. & Neary, D. (2001). Longitudinal evaluation of cognitive disorder in Huntington’s disease. Journal of the International Neuropsychological Society, 7, 33–44.
Sutherland, G.R. & Richards, R.I. (1993). Dynamic mutations on the move. Journal of Medical Genetics, 30, 978–981.
Testa, J.A. Brumback, R.A. et al.(1988). Neuropathology and memory dysfunction in neurodegeneraive diseases. In A. Troster (Ed.), Memory in neurodegenerative disease: Biological, Cognitive and Clinical Perspectives. CUP
Quinn N, Brown R, Craufurd D, Goldman S, Hodges J, Kieburtz K, Lindvall O, MacMIllan J, Roos R (1996). Core Assessment program for intracerebral transplantation in Huntington’s disease. Movement Disorders 1996 11: 143-150.
Zakzanis, K.K (1998). The subcortical dementia of Huntington’s disease. Journal of Clinical and Experimental Neuropsychology, 20, 4, 565–578.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag London Limited
About this chapter
Cite this chapter
Pender, N.P., Koroshetz, W.J. (2011). Huntington’s Disease. In: Hardiman, O., Doherty, C. (eds) Neurodegenerative Disorders. Springer, London. https://doi.org/10.1007/978-1-84996-011-3_8
Download citation
DOI: https://doi.org/10.1007/978-1-84996-011-3_8
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84996-010-6
Online ISBN: 978-1-84996-011-3
eBook Packages: MedicineMedicine (R0)